Streetbeat News

Price Targets

BKNG

Wedbush analyst Scott Devitt has maintained an Outperform rating on Booking Holdings (NASDAQ:BKNG) and increased the price target from $3300 to $3850, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 2:05 pm

OTLK

Capital One analyst Zegbeh Jallah has upgraded Outlook Therapeutics (NASDAQ:OTLK) from Equal-Weight to Overweight and set a price target of $5. This upgrade reflects a positive view on the company's prospects.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:58 pm

PINS

Wedbush analyst Scott Devitt has maintained a Neutral rating on Pinterest (NYSE:PINS) but increased the price target from $32 to $35.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:53 pm

META

Wedbush analyst Scott Devitt has maintained an Outperform rating on Meta Platforms (NASDAQ:META) and increased the price target from $350 to $420, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:51 pm

MELI

Wedbush analyst Scott Devitt has maintained an Outperform rating on MercadoLibre (NASDAQ:MELI) and increased the price target from $1700 to $1800.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:48 pm

IOVA

Truist Securities analyst Asthika Goonewardene has reiterated a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:46 pm

MIST

TD Cowen has maintained an Outperform rating on Milestone Pharmaceuticals (NASDAQ:MIST) but has reduced the price target from $17 to $9. This adjustment reflects a change in valuation expectations for MIST, although the Outperform rating indicates continued confidence in the company's performance.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:41 pm

FUSN

Fusion Pharmaceuticals' stock (FUSN) has been upgraded by Raymond James from Outperform to Strong Buy, with an increased price target from $12 to $15, leading to higher trading of the shares.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:40 pm

FUSN

Oppenheimer analyst Jeff Jones has reiterated an Outperform rating on Fusion Pharmaceuticals (NASDAQ:FUSN) and maintained a $13 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:36 pm

GLP

Stifel analyst Selman Akyol has reaffirmed a Buy rating on Global Partners (NYSE:GLP) and increased the price target from $40 to $44, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 27, 2023 | 1:31 pm